OR4D10

Summary

OR4D10 (olfactory receptor family 4 subfamily D member 10, HGNC:15173) is a protein-coding gene on chromosome 11q12.1, encoding Olfactory receptor 4D10 (Q8NGI6). Odorant receptor.

Olfactory receptors interact with odorant molecules in the nose, to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome.

Source: NCBI Gene 390197 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_001004705

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15173
Approved symbol	OR4D10
Name	olfactory receptor family 4 subfamily D member 10
Location	11q12.1
Locus type	gene with protein product
Status	Approved
Aliases	OST711
Ensembl gene	ENSG00000254466
Ensembl biotype	protein_coding
Entrez	390197

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000530162

RefSeq mRNA: 1 — MANE Select: NM_001004705 NM_001004705

CCDS: CCDS53636

Canonical transcript exons

ENST00000530162 — 3 exons

Exon	Start	End
ENSE00002164873	59477262	59479361
ENSE00003812866	59473315	59473641
ENSE00003813734	59473739	59473793

Expression profiles

Bgee: expression breadth tissue_specific, 2 present calls, max score 81.83.

Top tissues by expression

129 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.83	silver quality
cortical plate	UBERON:0005343	40.36	silver quality
sural nerve	UBERON:0015488	39.59	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
bone marrow	UBERON:0002371	31.74	gold quality
muscle tissue	UBERON:0002385	31.06	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
liver	UBERON:0002107	29.83	gold quality
prefrontal cortex	UBERON:0000451	29.20	gold quality
tonsil	UBERON:0002372	28.79	gold quality
duodenum	UBERON:0002114	28.14	gold quality
urinary bladder	UBERON:0001255	27.73	gold quality
lymph node	UBERON:0000029	27.57	gold quality
leukocyte	CL:0000738	26.97	gold quality
monocyte	CL:0000576	26.90	gold quality
islet of Langerhans	UBERON:0000006	26.55	gold quality
vermiform appendix	UBERON:0001154	26.42	gold quality
blood	UBERON:0000178	26.33	gold quality
gall bladder	UBERON:0002110	25.98	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	25.89	gold quality
placenta	UBERON:0001987	25.81	gold quality
right lobe of liver	UBERON:0001114	25.68	gold quality
muscle of leg	UBERON:0001383	25.04	gold quality
primary visual cortex	UBERON:0002436	24.61	gold quality
uterine cervix	UBERON:0000002	24.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.62

Regulation

Is transcription factor: no

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
mus_musculus	Or4d10c	ENSMUSG00000044994
mus_musculus	Or4d10	ENSMUSG00000067526
mus_musculus	Or4d10b	ENSMUSG00000067528
rattus_norvegicus	Or4d10	ENSRNOG00000067230
rattus_norvegicus	Or4d10c	ENSRNOG00000088521

Paralogs (130): OR1I1 (ENSG00000094661), OR12D3 (ENSG00000112462), OR7A10 (ENSG00000127515), OR7C2 (ENSG00000127529), OR7C1 (ENSG00000127530), OR1E2 (ENSG00000127780), OR1J1 (ENSG00000136834), OR1L4 (ENSG00000136939), OR4D1 (ENSG00000141194), OR4K1 (ENSG00000155249), OR3A3 (ENSG00000159961), OR7G1 (ENSG00000161807), OR1Q1 (ENSG00000165202), OR1K1 (ENSG00000165204), OR4K2 (ENSG00000165762), OR4D6 (ENSG00000166884), OR1F1 (ENSG00000168124), OR4K14 (ENSG00000169484), OR4K15 (ENSG00000169488), OR7G3 (ENSG00000170920), OR7G2 (ENSG00000170923), OR1M1 (ENSG00000170929), OR4D5 (ENSG00000171014), OR1L6 (ENSG00000171459), OR1L3 (ENSG00000171481), OR1L8 (ENSG00000171496), OR1N2 (ENSG00000171501), OR1N1 (ENSG00000171505), OR2AT4 (ENSG00000171561), OR1A1 (ENSG00000172146), OR1A2 (ENSG00000172150), OR4C11 (ENSG00000172188), OR4X2 (ENSG00000172208), OR4D9 (ENSG00000172742), OR10K1 (ENSG00000173285), OR1L1 (ENSG00000173679), OR7D4 (ENSG00000174667), OR4S2 (ENSG00000174982), OR4B1 (ENSG00000175619), OR4D11 (ENSG00000176200)

Protein

Protein identifiers

Olfactory receptor 4D10 — Q8NGI6 (reviewed: Q8NGI6)

Alternative names: Olfactory receptor OR11-251

All UniProt accessions (2): A0A126GVJ1, Q8NGI6

UniProt curated annotations — full annotation on UniProt →

Function. Odorant receptor.

Subcellular location. Cell membrane.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_001004705* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR000725	Olfact_rcpt	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR050427	Olfactory_Receptors	Family

Pfam: PF13853

UniProt features (17 total): topological domain 8, transmembrane region 7, chain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NGI6-F1	90.14	0.66

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 5

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9752946	Expression and translocation of olfactory receptors

MSigDB gene sets: 18 (showing top): GOBP_SENSORY_PERCEPTION_OF_CHEMICAL_STIMULUS, KEGG_OLFACTORY_TRANSDUCTION, GOBP_DETECTION_OF_STIMULUS, GOBP_SENSORY_PERCEPTION, GOMF_OLFACTORY_RECEPTOR_ACTIVITY, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, GOBP_SENSORY_PERCEPTION_OF_SMELL, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, GOBP_DETECTION_OF_STIMULUS_INVOLVED_IN_SENSORY_PERCEPTION, RAO_BOUND_BY_SALL4_ISOFORM_A, REACTOME_OLFACTORY_SIGNALING_PATHWAY, REACTOME_SENSORY_PERCEPTION, GOBP_DETECTION_OF_CHEMICAL_STIMULUS, GOMF_MOLECULAR_TRANSDUCER_ACTIVITY

GO Biological Process (4): signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186), sensory perception of smell (GO:0007608), detection of chemical stimulus involved in sensory perception of smell (GO:0050911)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), olfactory receptor activity (GO:0004984)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Olfactory Signaling Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transmembrane signaling receptor activity	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
sensory perception of chemical stimulus	1
sensory perception of smell	1
detection of chemical stimulus involved in sensory perception	1
G protein-coupled receptor signaling pathway	1
detection of chemical stimulus involved in sensory perception of smell	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

256 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OR4D10	TMEM202	A6NGA9	553
OR4D10	FOXD4L6	Q3SYB3	480
OR4D10	ZNF684	Q5T5D7	465
OR4D10	FBXO48	Q5FWF7	452
OR4D10	ZNF793	Q6ZN11	422
OR4D10	NUP62CL	Q9H1M0	411
OR4D10	FAM81B	Q96LP2	396
OR4D10	BHLHA9	Q7RTU4	395
OR4D10	ZNF616	Q08AN1	393
OR4D10	ZNF18	P17022	380
OR4D10	EFCAB13	Q8IY85	370
OR4D10	SLC22A24	Q8N4F4	370
OR4D10	ZNF611	Q8N823	368
OR4D10	UNC93A	Q86WB7	348
OR4D10	CCDC127	Q96BQ5	345

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A096LPK9, A0A0X1KG70, A6NHA9, A6NMZ5, P0C604, P0C623, P0C645, P0DN82, P58180, P58182, Q15615, Q60881, Q6IF82, Q8IXE1, Q8N0Y3, Q8NGA8, Q8NGB4, Q8NGB6, Q8NGC2, Q8NGC3, Q8NGD0, Q8NGD1, Q8NGD2, Q8NGD5, Q8NGE8, Q8NGF4, Q8NGF8, Q8NGF9, Q8NGI4, Q8NGI6, Q8NGJ0, Q8NGJ1, Q8NGL6, Q8NGM1, Q8NGN0, Q8NGN8, Q8NGX5, Q8NH05, Q8NH42, Q8NH49

Diamond homologs: A0A096LPK9, A0A0X1KG70, A6NHA9, A6NMZ5, O60412, O76099, O95013, P0C604, P0C623, P0C645, P0DN82, P23270, P23275, P58173, P58180, P58182, Q15615, Q60878, Q60881, Q60888, Q6IEV9, Q6IEY1, Q6IF82, Q7TQQ0, Q8IXE1, Q8N0Y3, Q8N628, Q8NGA8, Q8NGB2, Q8NGB4, Q8NGB6, Q8NGB8, Q8NGB9, Q8NGC2, Q8NGC3, Q8NGC4, Q8NGC6, Q8NGD0, Q8NGD1, Q8NGD2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

200 predictions. Top by Δscore:

Variant	Effect	Δscore
11:59477493:G:GT	donor_gain	0.9300
11:59477493:G:T	donor_gain	0.8900
11:59477501:C:G	donor_gain	0.8800
11:59477496:G:GG	donor_gain	0.8600
11:59477495:A:AG	donor_gain	0.8000
11:59477527:T:A	acceptor_gain	0.7900
11:59478271:T:TA	acceptor_gain	0.7900
11:59477452:GG:G	donor_gain	0.7500
11:59477453:GG:G	donor_gain	0.7500
11:59477500:GCT:G	donor_gain	0.7400
11:59478283:T:A	acceptor_gain	0.7300
11:59478291:A:AG	acceptor_gain	0.7300
11:59478276:A:AG	acceptor_gain	0.7000
11:59478197:T:G	acceptor_gain	0.6900
11:59478291:ACTCT:A	acceptor_gain	0.6800
11:59478295:T:TA	acceptor_gain	0.6400
11:59477492:GGAA:G	donor_gain	0.6300
11:59477660:A:AG	acceptor_gain	0.6300
11:59477661:G:GG	acceptor_gain	0.6300
11:59478289:A:AG	acceptor_gain	0.6300
11:59477491:GGGAA:G	donor_gain	0.6200
11:59477492:GGAAG:G	donor_gain	0.6200
11:59478278:C:G	acceptor_gain	0.6200
11:59477776:C:CA	acceptor_gain	0.6100
11:59478203:T:G	acceptor_gain	0.6100
11:59478292:C:G	acceptor_gain	0.6100
11:59478073:T:TA	acceptor_gain	0.5900
11:59478277:A:AG	acceptor_gain	0.5900
11:59478290:C:G	acceptor_gain	0.5900
11:59478255:A:AG	acceptor_gain	0.5600

AlphaMissense

2022 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:59477931:T:C	F168L	0.859
11:59477933:C:A	F168L	0.859
11:59477933:C:G	F168L	0.859
11:59477958:T:C	F177L	0.854
11:59477960:C:A	F177L	0.854
11:59477960:C:G	F177L	0.854
11:59478180:T:C	F251L	0.788
11:59478182:C:A	F251L	0.788
11:59478182:C:G	F251L	0.788
11:59478213:T:C	F262L	0.777
11:59478215:C:A	F262L	0.777
11:59478215:C:G	F262L	0.777
11:59478060:T:C	F211L	0.768
11:59478062:T:A	F211L	0.768
11:59478062:T:G	F211L	0.768
11:59477463:T:C	F12L	0.754
11:59477465:T:A	F12L	0.754
11:59477465:T:G	F12L	0.754
11:59477733:T:C	F102L	0.748
11:59477735:T:A	F102L	0.748
11:59477735:T:G	F102L	0.748
11:59477511:T:C	F28L	0.720
11:59477513:T:A	F28L	0.720
11:59477513:T:G	F28L	0.720
11:59478299:G:C	R290S	0.713
11:59478299:G:T	R290S	0.713
11:59478252:T:C	F275L	0.711
11:59478254:C:A	F275L	0.711
11:59478254:C:G	F275L	0.711
11:59477646:T:C	F73L	0.694

dbSNP variants (sampled 300 via entrez): RS1000330024 (11:59471876 G>A), RS1000345026 (11:59471426 A>C), RS1000691216 (11:59476486 T>A), RS1000721831 (11:59476219 T>C), RS1001267711 (11:59477335 C>A,T), RS1002073068 (11:59472336 C>T), RS1002939514 (11:59475752 A>T), RS1002970679 (11:59475451 A>C), RS1003617690 (11:59475671 G>A,C), RS1003682440 (11:59474624 A>G), RS1004527268 (11:59471803 T>C), RS1004616695 (11:59479781 A>C,G), RS1004881281 (11:59475140 T>C), RS1005486142 (11:59475323 A>G), RS1005813353 (11:59476622 T>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

2 total (human), top 2 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
tebuconazole	decreases expression	1
CGP 52608	affects binding, increases reaction	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial